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Death from breast carcinoma in a premenopausal patient 
has directed most physicians who are treating this disease 
to review their cases and search for 8. better means of 
improving the cure rate and extending the survival time 
of subsequent patients who present with this therapeutic 
problem. 
Advances in surgical technique, improved methods 
of irradiation therapy, the relatively recent use of new 
and better understood chemotherapeutic agents, and ther-
a.peutic castra.tion have failed to change the mortality rate 
in breast carcinoma since accurate records have been 
available. Breast cancer is the leading cause of carcinoma 
in females. The mortality rate for all females is 27 per 
100,000, however, in the 45-50 age group this figure is 
r 
45 per 100,000 and there is a ltnear increase to 113 per 
100,000 in the 75-80 a8e group_ (1) The American Cancer 
Society predicts 29,000 dea.ths and 67,000 new cases of 
breast cancer in 1969. 
This paper is underta.ken as a, review of the current 
concepts in one method of treatment that ha,s long been 
debated, frequently doubted, and usually supported or 
condemmed with insufficient da,ta.. This trea.tment is 
prophyla.ctic oophorectomy. 
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REVIEW OF THE LITERATURE 
An English surgeon named Cooper in 1832 was the first 
to observe clinically and pa.thologica.lly that there wa.s an 
increa.se in size of the tumor premenstrually and diminution 
a,fter the menopause. However, he appa.rently did not realize 
the significance of these changes as he made no propose,l as 
to the causal factors. Thera,peutic ca,stration was being 
done in the late Nineteenth Century and Schinzinger suggested 
ca,stra,tion in menstrua,ting women who developed this tumor 
before the ma,lignancy wa.s widespread. He left no report of 
performing this opera,tion. This was left to Beatson who in 
1896 reported improvement following castration in ca,ses of 
inoperable breast ma,lignancy. (26) Numerous reports of 
remissions appea,red in the literature a.s various practioners 
began to use castration in their a.rmamentarium against re-
current disea,se, the so-called therapeutic ca,stra,tion. 
Taylor in 1934 introduced the concept of radiation castra.-
tion a,s routine therapy B,ldlng with radical ma,stectomy in 
uncomplica,ted breast ca,rcinoma in premenopause,l women. 
His ba.sis of therapy wa,s that the decrea,sed ova.rian 
a,ctivi ty would have an inhibitory influence on the develop-
ment of meta,static deposits. (23) However, in 1939 he 
reviewed his 17 patients treated by this method and could 
show no significant difference in longevity from a. control 
group. In this review, Taylor introduced the term "pro-
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phyla,ctic castration. fI (24) 
Ada,ir in 1945 and Nathanson in 1951 both felt that the 
resul ts both pro and con tha.t were being reported for prophy-
la,ctic ca.stra,tion were from valid, well controlled studies 
but both concluded that the data they reviewed showed no 
improvement in longevity when compared to therapeutic cas-
tration. (9) (15) 
J. Shelton Horsley in 1937 became disss.tisfied with 
the poor results of radical ma,stectomy in young women 
and began surgically removing both ovaries in women under 
forty whenever a radical mastectomy was done f'or breast 
malignanc1'. He based his opera,tions on recent results of 
experimental work rela,ting estrogens to mammary carcinoma. 
and clinical results showing benefits of castra,tion in 
advanced disease. This series of patients has been followed 
and more comment a.s to long term results will be ma.de 
later in this paper. 
Treves in 1957 reported. a series of 152 patients who 
received prophylactic ca.stra.tion and compa.red these to a. 
group of 2893 who were treated with ra,dical mastectomy. 
Even though 84 of these patients were castra.ted with 
X-ra;;, and 26 continued to menstruate, his sta.tistics still 
showed increased longevity and a. longer interval before 
recurrence. In this article, Treves ste,tea that immediate 
cessation of ovarian function is manda.tory, however, the 
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average length of time from mastectomy to castration was 
8.7 months in X-ray ca,strated and 12.2 months in surgica.lly 
castrated! The degree of tumor involvement wa,s a~so much 
gres,ter in the ca,strated group than in the controls. (25) 
Even with his rather impressive results this a,uthor in a 
subsequent a,rticle in 1958 felt that ovarian ablation 
should be reserved for patients with metastatic or re-
current disea,se. (26) 
other studies that have been reported include a, study 
by Huck of 36 pa,tients treated by irradiation steriliza,tion 
which showed no increasE\l5 yea:r survival over a, matched con-
trol group. (7) Siegert reported a difference of 16 
months in onset of recurrence in radiation castra,ted women 
in a series of 347 tree,ted compared with 260 controls. (21) 
Smi th alid Smith showed an increased 5 yea,r survival time 
in 60 patients undergoing ca,stra,tion, however, 11 of these 
were postmenopa.usal and the control group was not matched as 
to a~e. (22) Patterson and Russell in a well designed and 
controlled study to eva,luate effects of ra.diation ca,stra,tion 
on breast carcinoma showed significant results at three' 
yea:rs but not necessarily significant results at five yea:rs 
which suggested to them tha,t although there was no clear-
out long term survival advantage, there was no real dis-
a.dvantage. (18) M. P. Cole in 1964 reported follow-up 
results on this series of Patterson and Russell. In 367 
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cases, 76 had recurrent or inoperable carcinomas. In the 
291 cases which were not far a.dvanced, she showed results 
which although not statistically significant did show a. 
definite trend towards increa.sed survival and increa.sed 
interval to metastasis. In this follow up, no mention 
is made as to length of time between ma.stectomy and castra-
tion. It should a.lso be mentioned that these cases were 
all radia,tion ca.stration. Even with this not favora,ble 
factor, she wa,s able to show a' beneficial trend. (2) 
Rannaes in a series of 66 patients felt that although 
their results were not necessaxily statistically sig-
nificant, they believed that there was a trend toward 
increa,sed survival and delay in recurrence of disease. (19) 
E. F. Lewison who has been a frequent contributor 
to the literature feels that the decision between prophy-
lactic and thera,peutic castra.tion is "The Doctor's Dilemma!" 
He personally favors prophylactic caatration by surgical 
means in women under age forty with stage II disea,se 
and by irradiation in women over forty with stage II 
disease. For all other pa.tients he reserves castra,tion 
only for therapeutic means. (12) He has never given his 
personal series in the articles which were reviewed for 
• this paper and apparently bases his therapy primarily on 
his own literature review in 1962 which has been widely 
quoted by other authors. His conclusion from this review 
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compa,ring prophylactic and therapeutic castration wa,s that 
there is a "well defined trend toward a, prolonged life 
expectancy and an improved survival rate" in patients 
treated with prophylactic castration. (11) 
Roseaberg and Uhlmann in 1959 reported their results 
wi th 78 castra,ted and 122 non-castrated females, a,ll of 
whom", had no signs of meta.stasis a.t the time of their 
mastectomy. Five year survival was used as a basis for 
compaxing the efficacy of castra,tion. Fifty-seven per-
cent of the castrated females and thirty-three per-cent of 
the non-castrated group survived 5 years. From these 
observations, the a.uthors advocated prophyla.ctic ca,stration 
in all women with caxcinoma of the breast who exhibited 
signs of ovarian function. (20) 
Kennedy, Mielke; and Fortuny published in 1964 what 
they felt to be the first studies comparing the relative 
values of prophylactic ca.stration and therapeutic castration. 
The senior author he.d written several previous articles 
and in each had stressed that the stUdies which were being 
followed dogmatically as guidelines to therapy were in-
adequa,te. Using 2,908 cases of breast carcinoma" they 
culled 119 who had had a, prophyla.ctic castration and 177 
who ha,d had a. therapeutic ca.stra.tion. These groups were equa,l 
in a.ll factors except tha.t there were more patients under-
going therapeutic castration who had more widespread disease. 
Therefore, two comparisons l'le:re m~lde in this study tone 
between total groups and one between patients with equal 
~olvement. In comparing the groups with equal involve-
ment, these autho:rs concluded: L Tha:!; prophylactic 
castration del~ed the onset of recurrent iisease. 2. 
Tha,t the interval from recurrence to death ws,s less in:; 
the prophylactic castrated group. 3. That the interval 
from initial tumor therapy to death was not sta.tiatically 
different in the two groups with equal involvement. (9) 
Kennedy has used this da.ta in other axticles as a ba.sis 
for his method of treatment. He has written that since 
ca,stration can serve as a, very' valuable guide to the hor-
monal responsiveness of a. tumor and, hence, responsiveness 
to further hormonal ablation treatment, it should be done 
only therapeutically. (8) Kennedy has also stressed tha.t 
the term ffprophylacticl! ca,stration is a, misnomer a.s it 
does not prevent recurrence of disea..se. Hence, he favors 
9 
use of the terms Ifea.rlylf and nla.te t ! castra,tion when referring 
to initia,l and recurrent therapy. 
As previously mentioned in this pa,per, probs.bly the 
first series of pa.tients receiving adequate follow-up 
wa,s begun by Horsley in 1937. (6) In 1962, J. S. Horsley, III, 
and G. W. Horsley reported follow-up on this series. 
Sixty-eight cases of adenocarcinoma were treated and fcllowed. 
Over;a.ll surviva.l rates at 5 and 10 years were 71% a.nd 47% 
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respectively. These studies did not have a control group 
and 17 patients received X-ray therapy. 
Roar Nissen-Meyer reported in 1967 the results of 
breast cancer treatment at the No~vegian Radium Hospital 
in two different series of patients. T'.ae first group was 
treated from 1932 to 1951 by radical mastectomy and post-
operative radiation. The second series was tree,ted from 
1957 to 1967 by the same methods with the addition of pro-
phylactic castra,tion. A 59% survival ra.te wa.s obtained in 
the first series and a 72% rate in the second series. 
Meyer wisely analyzed the survival curves and found that 
the first four years showed a divergency of the surviva.l 
rate curves in favor of the castrated group but after five years 
the curves converged. He concluded tha,t prophylactic castra.-
tion did not change the overall survival ra,te but did 
prolong surviva,l time. He also did steroid excretion 
studies on his patients and found that the ovaries ma~ 
continue to produce hormones for up to ten yeaxs after tIle 
menopause. Also noted in this series was no difference 
in the survival of pa,tients ca,strated by surgery or by 
irradiation. (16) 
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STUDIES OF HORMONE RELATIONSHIPS 
It is not \'1i thin the scope of this pa,per to extensively 
review the literature concerned solely with hormone studies 
which do not ha.ve clinical trials of thera.py. 
In 1919 Loeb reported the prevention of mammary cancer 
in fema.1e mice of e. special strain by castra,tion before the 
age of six months. (13) Lacassag-.ae was the first to 
report the c~cinogenic effect of estrogens on breasts of 
special strains of mice. (10) It has been argued that 
these mice are specially inbred and '91i11 develop carcinoma. 
even if left a.1one and also, the doses of estrogens used 
to produce brea.st tumors were astronomical. Investiga.tors 
have been unable to produce carginogenic changes in monkeys 
with estrogenic compounds. (28) 
There have been no prospective studies on this problem 
in humans, however, one notes that with the marked increase 
in estrogen usage in the pa.st thirty yea.rs there has been 
only one type of carcinoma. that ha.s had an increase in 
incidence, that of breast carcinoma in,;.m.all.e.s trea.ted with 
estrogens for prosta.tic carcinoma. (17) Many studies have 
a.ctua.l1y shown a Itprotective effect" of estrogen therapy, 
particularly in osteoporotic females who have shown less 
than the predicted number of cancers fol1owL~g prolonged 
estrogen therapy. (14) There is little doubt, however, 
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tha,t hormone therapy does promote the growth of cancer of 
the breast alrea,dy present. (29) 
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CASE STUDIES 
As a paxt of this thesis, the cases of bres.st ca.r-
cinoma treated by ra.dical ma.stectomy and prophylactic 
oophorectomy at the University of Nebraska., Cla.rkson 
~.[emorial and Methodist Hospi ta.ls were tabulated for a. 
nationwide study by Dr. Wilson of the University of Texas 
M:edica,l School. This da.ta. was taken from the medical 
records and is presented below. All pa.tients were men-
struating at the time of oophorectomy. One pa.tient ha.d 
duct cell carcinoma, the rema.inder being a.denocarcinoma. 
All tumors were less than four centimeters in diameter. 
DATE OF AXILLARY DATE OF 
MASTECTOMY NODES OOPHORECT01fi SURVIVAL STATUS RECURRENCE 
5/12/61 + 6/26/61 Alive 10/3/68 NO (;~O) 
6/20/58 
-
6/20/58 Alive 3/31/69 NO (40) 
3/31151 + 9/29/57 Dec'd 11l21/59 YES (4jl 
9/3/59 - 2/22/60 Alive 9j12/68 YES (47) 
2/16/54 + 3/12/54 Decfd 3/4/59 YES (43) 
1/28159 + 2110/59 Dectd 3/28/63 YES (39) 
12/13/66 + 1117/67 Alive 4/1/69 NO (44) 
2/8/68 + 2/26/68 Alive llj-q/68 NO (47) 
Numbers in ( ) incicate age a,t mastectomy. 
From these few cases one can readily see how important 
it is to pool the case material from many institutions 




In reviewing the a~ticles on prophylactic versus 
therapeutic oophorectomy one is impressed by most writers' 
pleas for good prospective studies on this perplexing 
problem. TWo studies are currently in progress, the 
Surgical Breast Adjuvant Study and theUniversity of Texa.s 
l,'fedical School Study. To be of significant va,lue these 
will need to be very long term studies as is well stressed 
in recent literature the continuing morta,lity after the 
usua,l five or ten year studies. 
One aspect of prophyla,ctic ca,stration that is gener-
ally a.greed upon is the time of oophorectomy. It should 
be done a.s soon s,fter the radica.l mastectomy as the patient r s 
condi tion will a,llow. G. W. Horsley has in the past per-
formed the oophorectomy while an assistant wa.s closing the 
ma.stectomy incision. (5) This is certainly fea,sible if 
the patient's condition is stable and m~ even carry a. lesser 
morbidity with only one anesthetic and post-opera,tive 
period. 
There is a principle of gynecological surgery that 
one should almost always remove the uterus when perform-
ing a. bila.teral oophorectomy. Only one a~ticle was found 
which stressed this pOint. (27) A personal communica.tion 
with members of the Gynecology Staff of the University of 
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Nebraska offered a€reement and two reasons: 1. This 
removes with little added morbidity and no added mortality 
a now useless and frequent neoplasm producing organ. 
2. If estrogen chemotherapy is given to the patient at 
a later date, how will one man8€e the troublesome bleeding 
which will occur? Whether a hysterectomy is performed 
is presently left up to the surgeon performing the oophor-
ectomy. If he feels comfortable in performing a. hyster~ 
ectomy and if he feels there will be no increa,sed mor-
bidity, it should probably be done. 
Whether irradiation castration is as effective a,s surgical 
castration is certainly debata.ble. The more recent a.rticles 
have stressed that all of their patients ha.ve stopped men-
struating, however, there is always a period of time 
following irradia,tion that the ova.ries continue to function 
and some patients will menstruate for severa,l months. 
Therefore, it would seem tha,t if one desires immediate 
cessation of ovarian function, surgival ca,stration is the 
method of choice. 
Some authors have discussed the psychological aspects 
of castrating Iii, young female. These certainly are impor-
tant and should not be forgotten in the conversations 
between the physician and the patient preopera.tively and 
during follow-up. There should be very few, if any, 
instances where if prophylactic oophorectomy would be of 
benef'i tit would be deferred beca.use of the patient f s 
psychological make-up. 
The University of Nebraska Hospital is quite active 
in reappraising the methods of' treating bres.at cancer. 
We a~e participating in the Surgical Breast Adjuvant 
study. In ea~ly 1967 prophyla,ctic ca,stration was not 
being recommended by some members of' the Department of 
Oncology since it was postulated by Dr. B. J. Kennedy 
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tha.t if a prophyla,ctic castrs.tion is performed it will be 
difficult to tell if the breast tumor is hormonally 
dependent. Dr. Kennedy also believes that if one compa~es 
prophylactic with therapeutic castration, there is no 
improvement in total surviva.l time. Some members of 
the University's Surgery and Oncology Departments now feel 
that there is a delay in recurrence if surgical prophy-
lactic castration is performed and survival time can be 
increased if chemotherapy is sta~ted at the time of re-
currence. Because of the Universityts involvement with 
the Breast Adjuvant Program, each premenopausal patient 
wi th carcinoma of the bres.st is given a prophyla.ctic 
castration according to instructions from the Study head-
quarters at Rosewell Pa~k Hospital, Buffalo, New York. 
This method is used so that no bias is shown as to which 
premenopausa.l patient will be castrated. This is a more 
accura.te method in order to compa.re the effects of pro-
phyla,ctic oophorectomy. 
No matter what the outcome of future studies on 
17 
breast cancer, one must always keep the paramount thought 
in mind that a high degree of suspicion and ea.rly dia,gnosis 
still a£fords the best chance of cure in this disease. 
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